| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
12,080,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
393,510 |
Avg
Vol: |
181,704 |
| 52
Week Range: |
$0.34 - $0.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Portage Biotech is a clinical stage immune-oncology company focused on overcoming immune resistance. Co. sources, nurtures and develops therapies for a variety of cancers, by funding, implementing product development strategies, clinical counsel/trial design, shared services, financial and project management to enable execution of commercially informed development plans. Co.'s drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms of check point inhibitors with scientific rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
